HOME >> BIOLOGY >> NEWS
Even the Immune System works with Pincers

Max-Planck-Scientists decipher central protein complex in the human immune system / Relevance for future therapies in allergies, autoimmune diseases and transplantation medicine

A key building block of the human immune system was identified up to the atomic detail using the method of x-ray crystallography by scientists of the Max-Planck-Institute for Biochemistry in Martinsried/Germany (Nature, 20. July 2000, S. 267-273). The protein complex, a mediator between the soluble and cellular compounds of the immune components in the blood, consists of an antibody and its respective receptor. Their dialogue in the immune system ensures that pathogenic germs which were previously labeled with antibodies are removed by receptor-equipped immune cells, eg macrophages. The identification of the structure and of the exact location of the interaction site between both proteins opens new possibilities not only for the therapy of diseases like allergies or autoimmune diseases, but also in the field of transplantation medicine.

The most important weapon in the defense of diseases in the human organism are Y-shaped antibodies, the so-called immunoglobulins (Ig). Many quintillions of antibodies with more than a trillion different specificities are found in the blood of the human body. These subdivide themselves - as within all mammals - into five different antibody types: IgM, IgG, IgA, IgD and IgE. Every class has its own particular characteristics that makes it possible to adopt a certain defense function. IgA for example, can be transported through the uppermost layer of the skin and is found in saliva, sweat and tears.

The well investigated immunoglobulin IgG is, with 80 percent, the most abundant antibody class in the circulation. It easily passes through walls of blood vessels or the placental barrier and confers, by this, passive immun
'"/>

Contact: Peter Sondermann
sonderma@biochem.mpg.de
49-89-85782701
Max-Planck-Gesellschaft
27-Jul-2000


Page: 1 2 3

Related biology news :

1. Immune systems attack dogs kept on genetic leash
2. Immune system drug may increase availability of liver transplants
3. Immune cells may help deliver cancer vaccines for children
4. Immune response depends on key molecule: Research
5. Applied Biosystems and Immune Tolerance Network announce immunology research agreement
6. Immune system component found common to both humans and worms
7. Immune cells SLAP internal signals together
8. Immune co-stimulation and the Kaposis virus
9. Immune system helps prevent tumors after all
10. Immune system chemical may predict worsening of coronary heart disease in women
11. UWs new Cell Systems Initiative welcomes Immunex collaboration

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Even the Immune System works with Pincers

(Date:2/23/2015)... Conn. , Feb. 23, 2015 NXT-ID, ... or the "Company"), a biometric authentication company focused on ... has filed provisional patent 62114357 for DISTRIBUTED ... this patent, NXT-ID introduces a new groundbreaking payment method. ... the payment account may only be accessed if both ...
(Date:2/12/2015)... 12, 2015   MedNet Solutions , a ... study management systems, has recently bolstered its ... iMedNet as the eClinical ... and healthcare consultants.  Building on the Program,s existing ... and numerous co-marketing opportunities), MedNet,s new and improved ...
(Date:2/9/2015)... Feb. 9, 2015  Lintec of America recently announced ... carbon nanotube (CNT) macrostructures, including sheets, yarns and ribbons, ... Leveraging the vast industrial resources of the ... , Lintec of America is forming the Nano-Science ... , focusing on scaling up the manufacturing and ...
Breaking Biology News(10 mins):NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4
(Date:3/4/2015)... , March 4, 2015  BioClinica®, Inc., ... technology provider, today announced that clinical trial ... convened at its annual European User Conference ... to discuss the use of its eClinical ... eClinical technologies include: the Microsoft Office-Smart OnPoint ...
(Date:3/4/2015)... California (PRWEB) March 04, 2015 ... (PCR) represents one of the fastest growing technologies in ... biologists in subcellular visualization is driving growth in nucleic ... for deeper understanding of gene expressions will continue to ... Expanding applications in fields ranging from pharma, biotech, food ...
(Date:3/4/2015)... 4, 2015 Lancée ... Paris en décembre 2011, l,étude collaborative ... », qui compare   l es microsphères ... sorafénib dans le carcinome hépatocellulaire avancé, a recruté ... foie avancé   ; les résultats sont attendus ...
(Date:3/3/2015)... March 3, 2015 /PRNewswire/ - Aptose Biosciences Inc. (NASDAQ: ... and molecular diagnostics that target the underlying mechanisms of ... seventh-month period ended December 31, 2014. Effective ... end from May 31 to December 31. As a ... today are for the quarter and the seven months ...
Breaking Biology Technology:BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 2BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 3Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 2Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 3Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 4Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 2Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 3Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 4Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 5Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 6Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 2Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 6Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 7Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 8Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 9Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 10Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 11Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 12
Cached News: